CDK4/6 inhibitor abemaciclib induces atypical cell-death with vacuolar formation by impairing lysosomal functions

被引：0
|
作者：
Hino, Hirotsugu [1 ]
Kazama, Hiromi [2 ]
Moriya, Shota [2 ]
Takano, Naoharu [2 ]
Hiramoto, Masaki [2 ]
Miyazawa, Keisuke [2 ]
机构：
[1] Nihon Univ, Div Anat Sci, Dept Funct Morpho, Sch Med, Tokyo, Japan
[2] Tokyo Med Univ, Dept Biochem, Tokyo, Japan
来源：
CANCER SCIENCE | 2021年 / 112卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PJ16-4-3
引用
收藏
页码：900 / 900
页数：1
相关论文
共 50 条
  • [31] Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib
    Gong, Xueqian
    Litchfield, Lacey M.
    Webster, Yue
    Chio, Li-Chun
    Wong, Swee Seong
    Stewart, Trent R.
    Dowless, Michele
    Dempsey, Jack
    Zeng, Yi
    Torres, Raquel
    Boehnke, Karsten
    Mur, Cecilia
    Marugan, Carlos
    Baquero, Carmen
    Yu, Chunping
    Bray, Steven M.
    Wulur, Isabella H.
    Bi, Chen
    Chu, Shaoyou
    Qian, Hui-Rong
    Iversen, Philip W.
    Merzoug, Farhana F.
    Ye, Xiang S.
    Reinhard, Christoph
    De Dios, Alfonso
    Du, Jian
    Caldwell, Charles W.
    Jose Lallena, Maria
    Beckmann, Richard P.
    Buchanan, Sean G.
    CANCER CELL, 2017, 32 (06) : 761 - +
  • [32] Abemaciclib, a CDK4/6 inhibitor, exerts preclinical activity against aggressive germinal center derived B-cell lymphomas
    Tanaka, Yuka
    Momose, Shuji
    Tabayashi, Takayuki
    Tokihira, Michihide
    Tamaru, Jun-ichi
    Kizaki, Masahiro
    CANCER SCIENCE, 2021, 112 : 547 - 547
  • [33] Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib
    La Monica, Silvia
    Fumarola, Claudia
    Cretella, Daniele
    Bonelli, Mara
    Minari, Roberta
    Cavazzoni, Andrea
    Digiacomo, Graziana
    Galetti, Maricla
    Volta, Francesco
    Mancini, Maicol
    Petronini, Pier Giorgio
    Tiseo, Marcello
    Alfieri, Roberta
    CANCERS, 2021, 13 (01) : 1 - 15
  • [34] The Novel CDK4/6-Inhibitor Abemaciclib Induces Early G1-Arrest in MCL Cell Lines, Sensitizes Cells to Cytarabine Treatment and Is Additive with Ibrutinib
    Fischer, Luca
    Schnaiter, Andrea
    Freysoldt, Bianca
    Irger, Markus
    Zimmermann, Yvonne
    Hutter, Grit
    Hiddemann, Wolfgang
    Dreyling, Martin H.
    BLOOD, 2015, 126 (23)
  • [35] The CDK4/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia
    Zhang, Jun
    Zhou, Lanlan
    Zhao, Shuai
    Dicker, David T.
    El-Deiry, Wafik S.
    CELL CYCLE, 2017, 16 (12) : 1193 - 1200
  • [36] Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors
    Patnaik, Amita
    Rosen, Lee S.
    Tolaney, Sara M.
    Tolcher, Anthony W.
    Goldman, Jonathan W.
    Gandhi, Leena
    Papadopoulos, Kyriakos P.
    Beeram, Muralidhar
    Rasco, Drew W.
    Hilton, John F.
    Nasir, Aejaz
    Beckmann, Richard P.
    Schade, Andrew E.
    Fulford, Angie D.
    Nguyen, Tuan S.
    Martinez, Ricardo
    Kulanthaivel, Palaniappan
    Li, Lily Q.
    Frenzel, Martin
    Cronier, Damien M.
    Chan, Edward M.
    Flaherty, Keith T.
    Wen, Patrick Y.
    Shapiro, Geoffrey I.
    CANCER DISCOVERY, 2016, 6 (07) : 740 - 753
  • [37] ABEMACICLIB, A SELECTIVE CDK4/6 INHIBITOR, RESTRICTS GROWTH OF PEDIATRIC GLIAL-LINEAGE TUMORS IN VITRO AND IN VIVO
    Liang, Muh-Lii
    Hsieh, Tsung-Han
    Wong, Tai-Tong
    NEURO-ONCOLOGY, 2020, 22 : 414 - 414
  • [38] Abemaciclib, an inhibitor of CDK4 and CDK6, combined with endocrine and HER2-targeted therapies for women with metastatic breast cancer
    Goetz, M. P.
    Beeram, M.
    Beck, T.
    Conlin, A. K.
    Dees, E. C.
    Dickler, M. N.
    Helsten, T. L.
    Conkling, P. R.
    Edenfield, W. J.
    Richards, D. A.
    Turner, P. K.
    Cai, N.
    Chan, E. M.
    Pant, S.
    Becerra, C. H.
    Kalinsky, K.
    Puhalla, S. L.
    Rexer, B. N.
    Burris, H. A.
    Tolaney, S. M.
    CANCER RESEARCH, 2016, 76
  • [39] Abemaciclib, a CDK4/6 inhibitor, exerts preclinical activity against aggressive germinal center-derived B-cell lymphomas
    Tanaka, Yuka
    Momose, Shuji
    Tabayashi, Takayuki
    Sawada, Keisuke
    Yamashita, Takahisa
    Higashi, Morihiro
    Sagawa, Morihiko
    Tokuhira, Michihide
    Rosenwald, Andreas
    Kizaki, Masahiro
    Tamaru, Jun-ichi
    CANCER SCIENCE, 2020, 111 (02) : 749 - 759
  • [40] The CDK4/CDK6 inhibitor abemaciclib inhibits transcriptional targets which facilitate growth in ER plus breast cancer cells
    McNulty, Ann M.
    Burke, Teresa
    Dempsey, Jack A.
    Marchal, Christophe C.
    Schade, Andrew E.
    Szpurka, Hadrian P.
    Dowless, Michele S.
    Stephens, Jennifer
    Stephens, Jennifer
    Edmondson, Denise
    Stayrook, Keith
    Caldwell, William C.
    Buchanan, Sean
    Merzoug, Farhana F.
    Beckmann, Richard P.
    MOLECULAR CANCER RESEARCH, 2016, 14
12345